Rituximab therapy in Waldenström’s macroglobulinemia (reviewed in Merlini and Treon21 ).
| Study . | Number of Patients . | Median Number of Courses . | Major RRa . | Median Response Duration . |
|---|---|---|---|---|
| a >50% reduction in serum IgM levels. | ||||
| Abbreviations: NA, not applicable; RR, response rate. | ||||
| Byrd | 6 | 4 | 57% | 6.6+ months |
| Weber | 7 | 4 | 75% | 9.0 months |
| Foran | 7 | 4 | 29% | NA |
| Treon | 30 | 4 | 27% | 8.0 months |
| Gertz | 69 | 4 | 27% | 27+ months |
| Dimopoulos | 27 | 8 | 44% | 16+ months |
| Treon | 26 | 8 | 48% | 29+ months |
| Study . | Number of Patients . | Median Number of Courses . | Major RRa . | Median Response Duration . |
|---|---|---|---|---|
| a >50% reduction in serum IgM levels. | ||||
| Abbreviations: NA, not applicable; RR, response rate. | ||||
| Byrd | 6 | 4 | 57% | 6.6+ months |
| Weber | 7 | 4 | 75% | 9.0 months |
| Foran | 7 | 4 | 29% | NA |
| Treon | 30 | 4 | 27% | 8.0 months |
| Gertz | 69 | 4 | 27% | 27+ months |
| Dimopoulos | 27 | 8 | 44% | 16+ months |
| Treon | 26 | 8 | 48% | 29+ months |